Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 6/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11188667 | 0.91 | MRGPRX4 (0.78) | MRGPRX4KCNH2PDE5APDE1APDE1B | |
| SCHEMBL22481085 | 0.85 | MRGPRX4 (1.00) | MRGPRX4KCNH2PDE5APDE1APDE1B | |
| SCHEMBL27703908 | 0.85 | MRGPRX4 (0.74) | MRGPRX4KCNH2PDE5APDE1APDE1B | |
| SCHEMBL22480814 | 0.84 | MRGPRX4 (0.68) | MRGPRX4KCNH2PDE5AGPBAR1 | |
| SCHEMBL4444817 | 0.84 | MRGPRX4 (0.64) | MRGPRX4KCNH2PDE5AMCL1PDE1A | |
| SCHEMBL14310387 | 0.84 | MRGPRX4 (0.60) | MRGPRX4KCNH2PDE5AMCL1PDE1A | |
| SCHEMBL4442894 | 0.83 | MRGPRX4 (0.59) | MRGPRX4KCNH2PDE5APDE1APDE1B | |
| SCHEMBL4444245 | 0.82 | MRGPRX4 (0.58) | MRGPRX4KCNH2MCL1PTGER4 | |
| SCHEMBL3562475 | 0.82 | MRGPRX4 (0.58) | MRGPRX4KCNH2PDE5AMCL1PDE1A | |
| SCHEMBL14261223 | 0.80 | PTPN1 (0.51) | MRGPRX4PDE5AMCL1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG A | 2008-05-08 | — | — | US | claimed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | claimed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | GYS2, GYS1, PYGL | MRGPRX4 2501/4885KCNH2 4529/4885PDE5A 1620/4885 |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | MRGPRX4 1798/4885KCNH2 4614/4885PDE5A 1351/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | MRGPRX4 1798/4885KCNH2 4614/4885PDE5A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.